Entero Therapeutics (ENTO) Projected to Post Earnings on Friday

Entero Therapeutics (NASDAQ:ENTO) is anticipated to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Entero Therapeutics Trading Down 7.6 %

NASDAQ:ENTO opened at $0.54 on Friday. The company has a fifty day moving average of $0.52 and a 200 day moving average of $0.53. Entero Therapeutics has a 52 week low of $0.19 and a 52 week high of $3.16.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.